It should be noted that twelve anti-TIM-3 clinical trials have already been initiated (clinicaltrials.gov, July 1st 2021).TIGIT and CD96 are other NK cell receptors that serve as an optimal target for NK-mediated cancer immunotherapy [94]. Here, HAVCR2 is linked to cancer.